Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.
Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?
PTC Therapeutics already sells a drug for Duchenne muscular dystrophy that does not work. Now, the drug maker is buying a second, approved Duchenne drug mired in a price-gouging controversy.
AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.